{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:21Z","timestamp":1790790201360,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"24","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,25]]},"DOI":"10.1093\/eurheartj\/ehad281","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T16:59:28Z","timestamp":1686329968000},"page":"2199-2201","source":"Crossref","is-referenced-by-count":12,"title":["Expanding indications for non-biopsy diagnosis of transthyretin amyloid cardiomyopathy"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1185","authenticated-orcid":false,"given":"Sharmila","family":"Dorbala","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 , USA"},{"name":"Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 , USA"},{"name":"CV imaging program, Cardiovascular Division and Department of Radiology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA 02115 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"2023062515033858600_ehad281-B1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 2 of 2\u2014diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2023062515033858600_ehad281-B2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2023062515033858600_ehad281-B3","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2023062515033858600_ehad281-B4","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023062515033858600_ehad281-B5","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2023062515033858600_ehad281-B6","first-page":"1076","article-title":"ACC Expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Writing Committee","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023062515033858600_ehad281-B7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2023062515033858600_ehad281-B8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2023062515033858600_ehad281-B9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2023062515033858600_ehad281-B10","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1093\/eurheartj\/ehac526","article-title":"The challenge of managing patients with light-chain cardiac amyloidosis: the value of cardiac magnetic resonance as a guide to the treatment response","volume":"43","author":"Damy","year":"2022","journal-title":"Eur Heart J"},{"key":"2023062515033858600_ehad281-B11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225","article-title":"Avoiding catastrophe: understanding free light chain testing in the evaluation of ATTR amyloidosis","volume":"14","author":"Witteles","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2023062515033858600_ehad281-B12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"2023062515033858600_ehad281-B13","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023062515033858600_ehad281-B14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-020-01771-3","article-title":"The renal range of the kappa\/lambda sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease","volume":"21","author":"Molina-Andujar","year":"2020","journal-title":"BMC Nephrol"},{"key":"2023062515033858600_ehad281-B15","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad139","article-title":"Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis","volume":"44","author":"Rauf","year":"2023","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/24\/2199\/50699862\/ehad281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/24\/2199\/50699862\/ehad281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T23:15:47Z","timestamp":1702509347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/24\/2199\/7191298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":15,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,6,7]]},"published-print":{"date-parts":[[2023,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad281","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,21]]},"published":{"date-parts":[[2023,6,7]]}}}